Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | BMC Neuroscience

Fig. 3

From: Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick’s disease and fronto-temporal tauopathies

Fig. 3

Western blot analysis of effects of CBL on levels of tau in 3R tau transgenic mice a Representative immunoblots of samples from the 3–6 month group analyzed with antibodies against 3R Tau tTau and p-tau (PHF1). b, c Image analysis of levels of 3R Tau and ratio of p-tau/tTau in the brains of mice from the 3–6 month group. d Representative immunoblots of samples from the 6–9 month group analyzed with antibodies against 3R Tau, tTau and p-tau (PHF1). e, f Image analysis of levels of 3R tau and p-tau/tTau in the brains of mice from the 6–9 month group. For analysis, N = 10 non-tg and N = 10 3R Tau tg mice from each age and treatment group. *P < 0.05 when compared to non-tg control using one way ANOVA with Dunnet’s post hoc test. # P < 0.05 when compared to vehicle-treated tg mice control using one way ANOVA with Dunnet’s post hoc test

Back to article page